These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17542745)

  • 1. Nasal influenza vaccine enters Phase I clinical trial.
    Expert Rev Vaccines; 2007 Jun; 6(3):305. PubMed ID: 17542745
    [No Abstract]   [Full Text] [Related]  

  • 2. [Vaccinal prevention of influenza in children].
    Zykov MP; Vasil'eva RI
    Tr Inst Im Pastera; 1982; 58():30-8. PubMed ID: 6764981
    [No Abstract]   [Full Text] [Related]  

  • 3. Nasoflu - a live influenza vaccine.
    Drug Ther Bull; 1976 Jan; 14(1):3-4. PubMed ID: 1245145
    [No Abstract]   [Full Text] [Related]  

  • 4. FluMist: an intranasal live influenza vaccine.
    Med Lett Drugs Ther; 2003 Aug; 45(1163):65-6. PubMed ID: 12915803
    [No Abstract]   [Full Text] [Related]  

  • 5. Live attenuated intranasal influenza vaccine.
    Belshe RB; Couch RB; Glezen WP; Treanor JT
    Vaccine; 2002 Oct; 20(29-30):3429-30. PubMed ID: 12297386
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children.
    Bracco Neto H; Farhat CK; Tregnaghi MW; Madhi SA; Razmpour A; Palladino G; Small MG; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2009 May; 28(5):365-71. PubMed ID: 19395948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experience in using an absorbed influenza chemical vaccine for the immunization of donors in producing anti-influenzal gamma-globulin].
    Egorov PA; Isupov FG; Tuĭmedova RA; Afanas'eva GA; Lobanova AM
    Tr Inst Im Pastera; 1976; 47():163-6. PubMed ID: 80045
    [No Abstract]   [Full Text] [Related]  

  • 8. A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children.
    Breiman RF; Brooks WA; Goswami D; Lagos R; Borja-Tabora C; Lanata CF; Londoño JA; Lum LC; Rappaport R; Razmpour A; Walker RE; Gruber WC; Forrest BD
    Vaccine; 2009 Sep; 27(40):5472-9. PubMed ID: 19616493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events associated with intranasal influenza vaccine in the United States.
    Vasu N; Ghaffari G; Craig ET; Craig TJ
    Ther Adv Respir Dis; 2008 Aug; 2(4):193-8. PubMed ID: 19124371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunogenic and reactogenic properties of inactivated influenza vaccine purified and concentrated by gradient centrifugation].
    Malikova EV; Safonova LS; Zueva LP; Znakova GM
    Tr Inst Im Pastera; 1982; 57():122-3. PubMed ID: 6763376
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and efficacy of influenza vaccine in children.
    Goldstein LG
    Ann Pharmacother; 2003 Nov; 37(11):1712-5. PubMed ID: 14565808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation data from experimental series on a killed influenza vaccine purified and concentrated by differential and density gradient centrifugation. II. The results of a study of the reactogenic properties of the vaccine].
    Karpukhin GI; Popov IV; Malikova EV
    Tr Inst Im Pastera; 1976; 47():156-9. PubMed ID: 802567
    [No Abstract]   [Full Text] [Related]  

  • 13. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
    Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
    Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
    Piedra PA; Gaglani MJ; Kozinetz CA; Herschler GB; Fewlass C; Harvey D; Zimmerman N; Glezen WP
    Pediatrics; 2007 Sep; 120(3):e553-64. PubMed ID: 17698577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of an attenuated, live, bivalent, influenza vaccine in children.
    Burech DL; Koranyi KI; Haynes RE
    Ohio State Med J; 1976 Jul; 72(7):385-7. PubMed ID: 934582
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.
    Van Kampen KR; Shi Z; Gao P; Zhang J; Foster KW; Chen DT; Marks D; Elmets CA; Tang DC
    Vaccine; 2005 Jan; 23(8):1029-36. PubMed ID: 15620476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technology evaluation: FluINsure, ID Biomedical.
    Munoz FM
    Curr Opin Mol Ther; 2004 Apr; 6(2):212-20. PubMed ID: 15195934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal influenzavirus vaccine in children.
    Dumois J
    N Engl J Med; 1998 Sep; 339(13):922-3. PubMed ID: 9750092
    [No Abstract]   [Full Text] [Related]  

  • 20. Intranasal flu vaccine available this season.
    Piascik P
    J Am Pharm Assoc (2003); 2003; 43(6):728-30. PubMed ID: 14717271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.